Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital

Huddar, Akshata; Bindu, Parayil Sankaran; Nagappa, Madhu; Bharath, Rose Dawn; Sinha, Sanjib; Mathuranath, P. S.; Taly, Arun B.

doi:10.4103/0028-3886.241404

Cited by 10 publications

(11 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, anti-NMDA-r encephalitis is triggered by infections (22), several other vaccines (23)(24)(25)(26)(27), and the YF vaccine (28,29); as such, anti-NMDA-r encephalitis could represent a novel YEL-AND. Opsoclonusmyoclonus-ataxia is considered a paraneoplastic or parainfectious disease, which is associated with several infections (30)(31)(32)(33), other vaccines (34)(35)(36)(37)(38)(39), and 1 case of YEL-AND described by Martins et al (4).…”

Section: Discussionmentioning

confidence: 99%

Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018

Ribeiro¹,

Guedes²,

Sulleiman³

et al. 2021

Emerg. Infect. Dis.

View full text Add to dashboard Cite

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page XXX.

show abstract

Section: Discussionmentioning

confidence: 99%

Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018

Ribeiro¹,

Guedes²,

Sulleiman³

et al. 2021

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…A slight female predilection (55%) highlighted in our study, is also supported by others. 1,2,13 The exact cause of OMAS in patients with NB is unclear. Presence of antineuronal antibodies in the sera and cerebrospinal fluid, increase in the proportion of CD19 + B-cells and gamma-delta T-cells in the cerebrospinal fluid and remission of neurologic symptoms with immunomodulatory therapy points toward an underlying immune-mediated cause.…”

Section: Discussionmentioning

confidence: 99%

“…O psoclonus-myoclonus-ataxia syndrome (OMAS) is a rare neuroinflammatory disorder associated with neuroblastoma (NB) in nearly 50% of cases. 1,2 Being associated with low-risk NB, they have a favorable oncologic outcome. 1,3 In contrast, the neurologic course of NB-OMAS is complicated by its relapsing nature and long-term neurobehavioral sequelae.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting

Anand

Agarwala²,

Jain³

et al. 2021

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Children with neuroblastoma (NB) and opsoclonus-myoclonus-ataxia syndrome (OMAS) have a favorable oncologic outcome and overall survival. In contrast, despite intensive multidrug immunomodulation, the neurologic outcome is complicated by the relapsing nature of the neurologic symptoms and long-term neurobehavioral sequelae. Being associated with low-risk NB, there exists an ambiguity in the current literature regarding the administration of chemotherapy in these children. We reviewed our archives for children with NB-OMAS over a 22-year (January 1996 to January 2018) period. Eighteen children (10 female) with a median age at diagnosis of 23 months had NB-OMAS and were included. They had stage 1 (9/18; 50%), 2 (1/18; 5.5%), 3 (7/18; 39%), and 4 (1/18; 5.5%) disease according to the International Neuroblastoma Staging System. Multimodality therapy included surgery (16/18; 89%), chemotherapy (11/18; 61%), and immunomodulatory therapy (10/18; 55%). Complete oncologic remission was achieved in all children. Relapse of OMAS and presence of neurologic sequelae were observed in 1 (5.5%) and 5 (28%) cases, respectively. Presence of neurologic sequelae was significantly associated with low-tumor stage (P=0.036) and treatment without chemotherapy (P=0.003). Chemotherapy administration was the only variable significantly predicting a favorable neurologic outcome (95% confidence interval: 0.26-1.40, P=0.01). To conclude, our study including a limited cohort of patients highlights a favorable neurologic outcome associated with chemotherapy administration in children with NB-OMAS. However, further studies with larger sample size need to be conducted before drawing any definite conclusions.

show abstract

“…Entre las infecciones se encuentran que se han relacionado se encuentra el HIV, tanto la seroconversión como durante la fase de reconstitución inmune posterior al inicio de terapia antiretroviral, el Mycoplasma pneumoniae, Salmonella enterica, rotavirus, citomegalovirus, herpes virus tipo 6 , hepatitis C, Coxsackie, influenza y Rickettsia conorii. También, se han reportado casos relacionados al contacto con dengue, malaria, varicela zoster y virus del nilo occidental (5,7,8); y otros ligados el uso de fármacos, como cefepime y en la intoxicación con venlafaxina (9,10).…”

Section: Métodounclassified

Síndrome opsoclonus - mioclonus

2020

View full text Add to dashboard Cite

El síndrome opsoclonus-mioclonus es una condición rara, asociada con una etiología de carácter autoinmune, tanto paraneoplásica, parainfecciosa o idiopática. Estos pacientes se presentan con ataxia del tronco y extremidades, con caídas, opsoclonus, mioclonías, y se puede acompañar de diversos grados de encefalopatía, signos cerebelosos y alteraciones del sueño. En el caso de la población pediátrica, se debe evaluar por neuroblastoma; y en adultos con encefalopatía asociada se debe realizar una evaluación exhaustiva para detectar malignidad oculta. Mientras que los síntomas neurológicos agudos pueden controlarse mediante inmunoterapia, y se ha visto respuesta parcial a tratamiento antitumoral, el resultado a largo plazo se caracteriza por la presencia de déficit neuropsicológico.

show abstract

Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital

Cited by 10 publications

References 2 publications

Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018

Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018

Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting

Síndrome opsoclonus - mioclonus

Contact Info

Product

Resources

About